At a time when women’s health attracts less than 2% of global research and development (R&D) and venture capital investment, the Women’s Health Impact Fund (WHIF) stands as the first venture capital fund in Europe exclusively dedicated to women’s health and femtech innovation – a historic milestone that redefines both social contribution and investment opportunities on the continent.
Pre-launched on August 1, 2025 by Greece, WHIF marks a groundbreaking moment for European innovation – bridging the long-standing gap in women’s health financing with a science-based, impact-focused investment strategy.
Founded and led by Ms. Areti Kalogerogianni, WHIF will invest across the full spectrum of women’s health – from reproductive care and pregnancy to menopause, chronic conditions, mental health, longevity and prevention – leveraging artificial intelligence, biotechnology and digital health to unlock scalable solutions.
As the first fund of its kind in Europe, WHIF directly addresses the imbalance between the €340 million of femtech investments in Europe in 2024 and the $1 trillion global market opportunity (WEF – McKinsey source) and in research.
Unlike later entrants or fund-of-funds models, WHIF’s direct early-stage investment approach ensures that capital flows where it is needed most, to founders who create measurable impact and sustainable returns.
“We don’t follow a trend, we create it,” says Areti Kalogerogianni, Founder and Managing Partner of WHIF. “While others were waiting for confirmation, we acted by seeing the future of al, science, femtech.”
With an international work experience and mindset, from New York to London, Dubai and now Athens, she has built her career connecting innovation, strategy and impact across continents. “My journey has never been about sticking to a system, but building a new one. Every step, from investment banking to global partnerships — has led to this moment: the creation of WHIF.”
WHIF is created for purpose, not privilege, with no institutional or political support at this time. Our mission is clear: to make women’s health a pillar of innovation, investment, and equality.
WHIF’s flagship MenoTracker is Europe’s first AI platform for menopause and hormonal health, launched in beta in September 2025 in partnership with Rocket Health. Already with over 1,000 users, it turns symptom tracking into actionable insights, reshaping research and empowering women through data.
In line with WHIF’s vision, the Women’s Health initiative at HLTH 2025 in America last October has now confirmed the global momentum predicted by Areti, validating that women’s health is the next frontier of innovation. WHIF aims to invest in innovative startups by 2026, expanding its network of strategic partnerships across Europe and beyond.
Join the women’s health revolution Founders – investors Www.whif.eu